Loading...
Market
Revenue growth of Calliditas Therapeutics post-acquisition
5
Asahi Kasei•Swedish•Calliditas Therapeutics AB•American Depositary Share•ADS•Sofinnova Partners•Amolyt Pharma•LimFlow•Calliditas Therapeutics
Resolution / Starting Odds
Significant growth in revenue • 25%
Moderate growth in revenue • 25%
Revenue remains stable • 25%
Revenue declines • 25%
Financial reports and industry news
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in $1.05b Offer
May 28, 2024, 08:27 AM
Asahi Kasei has announced its acquisition of Swedish drugmaker Calliditas Therapeutics AB for approximately $1.1 billion. The deal will see Asahi Kasei paying SEK 416, or about USD $39.37 in cash per American Depositary Share (ADS). This acquisition marks the third successful exit for Sofinnova Partners, following the recent exits of Amolyt Pharma and LimFlow. Calliditas Therapeutics, known for its focus on rare diseases, will be integrated into Asahi Kasei's expanding pharmaceutical portfolio. The acquisition offer was valued at $1.05 billion.
View original story
Similar markets
Increase over 10% • 33%
Decrease • 33%
Little to no change • 34%
Stock price rises significantly • 25%
Stock price remains stable • 25%
Stock price fluctuates moderately • 25%
Stock price falls significantly • 25%
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Less than $10 million • 33%
$10 million to $20 million • 33%
More than $20 million • 33%